May 11, 2021 - 1:26 PM
BURNABY, British Columbia (AP) _ Xenon Pharmaceuticals Inc. (XENE) on Tuesday reported a loss of $15.8 million in its first quarter.
On a per-share basis, the Burnaby, British Columbia-based company said it had a loss of 42 cents.
The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 45 cents per share.
The gene therapy biotech company posted revenue of $4.4 million in the period, also beating Street forecasts. Four analysts surveyed by Zacks expected $3.7 million.
Xenon Pharmaceuticals shares have climbed 17% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $17.93, a climb of 39% in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XENE at https://www.zacks.com/ap/XENE
News from © The Associated Press, 2021